Home Cart Sign in  
Chemical Structure| 1857417-13-0 Chemical Structure| 1857417-13-0

Structure of MI-503
CAS No.: 1857417-13-0

Chemical Structure| 1857417-13-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

MI-503 is a small molecule inhibitor of themenin-MLL interaction.

Synonyms: MI-503

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of MI-503

CAS No. :1857417-13-0
Formula : C28H27F3N8S
M.W : 564.63
SMILES Code : N#CC(N1CC2=CNN=C2)=CC3=C1C=CC(CN4CCC(NC5=C(C=C(CC(F)(F)F)S6)C6=NC=N5)CC4)=C3C
Synonyms :
MI-503
MDL No. :MFCD28506303
InChI Key :DETOMBLLEOZTMZ-UHFFFAOYSA-N
Pubchem ID :91667931

Safety of MI-503

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of MI-503

epigenetics

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
MLL-Af4 Lin- cells 0.2 μM, 1.0 μM 4 days To assess the effect of MI-503 on IGF2BP3 expression in MLL-Af4 Lin- cells, results showed that MI-503 treatment led to a dose-dependent decrease in IGF2BP3 expression. PMC10824693
MV4;11 human leukemia cells 0.2-0.6 μM 10 days Inhibited cell proliferation, GI50 value of 200 nM PMC4415852
MLL-AF9 transformed bone marrow cells 0.22 μM 7 days Inhibited cell growth, GI50 value of 0.22 μM PMC4415852
Mouse embryonic fibroblasts 1 μM 10 days MI-503 increased iCM reprogramming efficiency PMC5113048
Hep3B 2 μM 6 days Inhibited proliferation of Hep3B cells, reduced cell migration and sphere formation PMC5752584
HepG2 2 μM 6 days Inhibited proliferation of HepG2 cells, reduced cell migration and sphere formation PMC5752584
Ewing sarcoma cell lines 3 µM 72 h To evaluate the changes in newly transcribed mRNAs after MI-503 treatment, results showed that MI-503 treatment led to widespread changes in metabolic programs, with serine biosynthesis being the most significantly down-regulated pathway. PMC6388767

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice MLL leukemia model Intraperitoneal injection 60 mg/kg Once daily for 38 days Significantly inhibited tumor growth, tumor volume reduced by over 80% PMC4415852
Mice HepG2 and Hep3B xenograft models Intraperitoneal injection 35 mg/kg Once daily for 2-3 weeks MI-503 significantly inhibited tumor growth in HepG2 and Hep3B xenograft models, with enhanced effects when combined with sorafenib PMC5752584

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.77mL

0.35mL

0.18mL

8.86mL

1.77mL

0.89mL

17.71mL

3.54mL

1.77mL

References

 

Historical Records

Categories